# US 2001/0025111 A1 · Substituted 3,3-diamino-2-propenenitriles, their preparation and use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0025111 A1
- Document ID: US20010025111A1
- Status: Published application
- Kind: A1
- Application number: 09/848,054
- Filed: 2001-05-03
- Published: 2001-09-27
- Earliest claimed: 1998-11-05
- Inventors: John Bondo Hansen; Tina Moller Tagmose; John Patrick Mogensen; Florencio Zaragoza Dorwald; Anker Steen Jorgensen
- Web page: https://patentgrep.com/patent/US20010025111A1

## CPC

- C07C 317/48: the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07D 277/62: Benzothiazoles
- C07D 317/66: Nitrogen atoms not forming part of a nitro radical
- C07C 2601/04: with a four-membered ring
- C07C 2601/08: the ring being saturated
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Substituted cyanoenamines of the general formula I 1 wherein Z, R1, R2 and R3 are defined in the description, compositions thereof and methods for preparing the compounds are described. The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.

## Claims

### Claim 1

A compound of the general formula I 7
wherein
R1 is alkyl optionally substituted with halogen, hydroxy, alkoxy, aryloxy, alkylthio, arylthio, dialkylamino, arylalkylamino or diarylamino; or aralkyl optionally substituted with alkyl, trifluoromethyl, aryl, a 5-, 6- or 7-membered heterocyclic system, halogen, alkoxy, methylenedioxo, aryloxy, dialkylamino, alkylarylamino, diarylamino, nitro, alkylsulfonyl, arylsulfonyl, cyano, alkoxycarbonyl or aminocarbonyl; or aryl optionally substituted with alkyl, trifluoromethyl, aryl, a 5-, 6- or 7-membered heterocyclic system, halogen, alkoxy, methylenedioxo, aryloxy, dialkylamino, alkylarylamino, diarylamino, nitro, alkylsulfonyl, arylsulfonyl, cyano, alkoxycarbonyl or aminocarbonyl; or a 5-, 6- or 7-membered heterocyclic system optionally substituted with alkyl, aryl, a 5-, 6- or 7-membered heterocyclic system, halogen, alkoxy, aryloxy, dialkylamino, alkylarylamino, diarylamino, nitro, alkylsulfonyl, arylsulfonyl, cyano, alkoxycarbonyl or aminocarbonyl;
R2 and R3 are independently hydrogen; or alkyl optionally substituted with aryl, a 5-, 6- or 7-membered heterocyclic system, halogen, hydroxy, alkoxy, aralkoxy, aryloxy, alkylthio, arylthio, dialkylamino, arylalkylamino or diarylamino; or aryl optionally substituted with alkyl, aryl, a 5-, 6- or 7-membered heterocyclic system, halogen, trifluoromethyl, alkoxy, aryloxy, dialkylamino, alkylarylamino, diarylamino, nitro, alkylsulfonyl, arylsulfonyl, cyano, alkoxycarbonyl or aminocarbonyl; or
a 5-, 6- or 7-membered heterocyclic system optionally substituted with alkyl, aryl, a 5-, 6- or 7-membered heterocyclic system, halogen, alkoxy, aryloxy, dialkylamino, alkylarylamino, diarylamino, nitro, alkylsulfonyl, arylsulfonyl, cyano, alkoxycarbonyl or aminocarbonyl; or R2 and R3 are linked together by —(CH2)n—, n being 4-7, provided that R2 and R3 cannot be hydrogen at the same time;
Z is hydrogen, cyano, carbonylalkyl, alkoxycarbonyl, optionally substituted aminocarbonyl, alkylsulfonyl optionally substituted with alkyl, aryl, a 5-, 6- or 7-membered heterocyclic system, halogen, alkoxy, aryloxy, dialkylamino, alkylarylamino, diarylamino, nitro, alkylsulfonyl, arylsulfonyl, cyano, alkoxycarbonyl or aminocarbonyl; or arylsulfonyl optionally substituted with alkyl, aryl, a 5-, 6- or 7-membered heterocyclic system, halogen, alkoxy, aryloxy, dialkylamino, alkylarylamino, diarylamino, nitro, alkylsulfonyl, arylsulfonyl, cyano, alkoxycarbonyl or aminocarbonyl; or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form as well as metabolites or prodrugs.

### Claim 2 (depends on 1)

A compound according to claim 1 wherein Z is alkylsulfonyl or arylsulfonyl substituted with halogen.

### Claim 3 (depends on 1, 2)

A compound according to claim 1 or 2 wherein R1 is optionally substituted aryl.

### Claim 4 (depends on 3)

A compound according to claim 3 wherein R1 is optionally substituted phenyl.

### Claim 5 (depends on 4)

A compound according to claim 4 wherein R1 is phenyl substituted by one or two perhalomethyl groups.

### Claim 6 (depends on 4)

A compound according to claim 4 wherein R1 is phenyl substituted by one or two alkoxy groups.

### Claim 7 (depends on 4)

A compound according to claim 4 wherein R1 is phenyl substituted by one or two halogen groups.

### Claim 8 (depends on 4)

A compound according to claim 4 wherein R1 is phenyl substituted by one or two cyano groups.

### Claim 9 (depends on 5, 6, 7, 8)

A compound according to claim 5, 6, 7 or 8 wherein R2 is cyclic alkyl, preferably cyclobutyl.

### Claim 10 (depends on 5, 6, 7, 8)

A compound according to claim 5, 6, 7 or 8 wherein R2 is alkyl, preferably 1,1-dimethylpropyl.

### Claim 11

A compound selected from the group consisting of:
3-[3,5-bis(trifluoromethyl)phenylamino]-2-(4-chlorophenylsulfonyl)-3-(1,2,2-trimethylpropylamino)-2-propenenitrile
3-[3,5-bis(trifluaromethyl)phenylamino]-2-(4-chlorophenylsulfonyl)-3-cyclopentylamino-2-propenenitrile
3-[3,5-bis(trifluoromethyl)phenylamino]-2-(4chlorophenylsulfonyl)-3-isopropylamino-2-propenenitrile
3-[3,5-bis(trifluoromethyl)phenylamino]-2-(4-chlorophenylsulfonyl)-3-cyclobutylamino-2-propenenitrile
3-[3,5-bis(trifluoromethyl)phenylamino]-2-(4-chlorophenylsulfonyl)-3-propylamino-2-propenenitrile
2-(4-Chlorophenylsulfonyl)-3-(pyridin-3-ylamino)-3-(1,2,2-trimethylpropylamino)-2-propenenitrile
2-(4-Chlorophenylsulfonyl)-3-(3,5-dichlorophenylamino)-3-(1,2,2-trimethylpropylamino)-2-propenenitrile
3-(Benzo[1,3]dioxol-5-ylamino)-2-(4-chloro-phenylsulfonyl)-3-(1,2,2-trimethyl-propylamino)-propenenitrile
3-(3,5-Bis(trifluoromethyl)phenylamino)-2-methylsulfonyl-3-(1,2,2-trimethylpropylamino)-propenenitrile
2-(4-Chlorophenylsulfonyl)-3-(3,5-dimethoxyphenylamino)-3-(1,2,2-trimethylpropylamino)-2-propenenitrile
3-[N-(3,5-bis(trifluoromethyl)phenyl)-N-methylamino]-2-(4-chlorophenylsulfonyl)-3-(1,2,2-trimethylpropylamino)-2-propenenitrile
(1′S,2′S)-3-[2-Benzyloxycyclopentylamino]-3-[3,5-bis(trifluoromethyl)phenylamino]-2-(4-chlorophenylsulfonyl)-2-propenenitrile
(1′R,2′R)-3-[2-Benzyloxycyclopentylamino]-3-[3,5-bis(trifluoromethyl)phenylamino]-2-(4-chlorophenylsulfonyl)-2-propenenitrile
(S)-3-[3,5-Bis(trfluoromethyl)phenylamino]-2-(4-chlorophenylsulfonyl)-3-(1,2,2-trimethylpropylamino)-2-propenenitrile
(S)-3-[3,5-Bis(trifluoromethyl)phenylamino]-2-(4-chlorophenylsulfonyl)-3-(1,2-dimethylpropylamino)-2-propenenitrile
(R)-3-[3,5-Bis(trifluoromethyl)phenylamino]-2-(4-chlorophenylsulfonyl)-3-(1,2-dimethylpropylamino)-2-propenenitrile
3-[3,5-Bis(trifluoromethyl)phenylamino]-2-(4-chlorophenylsulfonyl)-3-(1,1-dimethylpropylamino)-2-propenenitrile
3-[3,5-Bis(trifluoromethyl)phenylamino]-2-(4chlorophenylsulfonyl)-3-(5-cyclopropyl-2-methyl-2H-pyrazol-3-ylamino)-2-propenenitrile
(R)-3-[3,5-bis(trifluoromethyl)phenylamino]-2-(4-chlorophenylsulfonyl)-3-(1,2,2-trimethylpropylamino)-2-propenenitrile
3-(3,5-Bis(trifluoromethyl)phenylamino)-3-isopropylamino-2-methylsulfonyl-propenenitrile
(R)-3-[3,5-bis(trifluoromethyl)phenylamino]-2-methanesulfonyl-3-(1,2,2-trimethylpropylamino)-2-propenenitrile
(S)-3-[3,5-bis(trifluoromethyl)phenylamino]-2-methanesulfonyl-3-(1,2,2-trimethylpropylamino)-2-propenenitrile
2-(4-Chlorophenylsulfonyl)-3-(3,5-dimethoxyphenylamino)-3-(1,1dimethylpropylamino)-2-propenenitrile
2-(4-Chlorophenylsulfonyl)-3-(3,5-dimethoxyphenylamino)-3-cyclobutylamino-2-propenenitrile
3-(3,5-dimethoxyphenylamino)-2-methanesulfonyl-3-(1,2,2-trimethylpropylamino)-propenenitrile
3-(3,5-dimethoxyphenylamino)-3-isopropyl-2-methanesulfonyl-propenenitrile
3-(Benzo[1,3]dioxol-5-ylamino)-3-(1,1 -dimethyl-propylamino)-2-(4-chloro-phenylsulfonyl)-propenenitrile
3-(Benzo[1,3]dioxol-5-ylamino)-3-cyclobutylamino-2-(4-chloro-phenylsulfonyl)-propenenitrile
2-(4-Chlorophenylsulfonyl)-3-(3,5-dichlorophenylamino)-3-(1,1 -dimethylpropylamino)-2-propenenitrile
2-(4-Chlorophenylsulfonyl)-3-cyclobutylamino-3-(3,5-dichlorophenylamino)-2-propenenitrile
3-sec-Butylamino-2-(4-chlorophenylsulfonyl)-3-(3,5-dichlorophenylamino)-2-propenenitrile
2-Methylsulfonyl-3-(3-methoxy-5-trifluoromethyl-phenylamino)-3-(1,2,2-trimethylpropylamino)-propenenitrile
3-(3-Fluoro-5-trifluoromethyl-phenylamino)-2-methylsulfonyl-3-(1,2,2-trimethylpropylamino)-propenenitrile
3-(4-Chlorophenylamino)-2-methylsulfonyl-3-(1,2,2-trimethylpropylamino)-acrylonitrile
3-(Benzothiazol-6-ylamino)-3-(1,1-dimethyl-propylamino)-2-methylsulfonyl-propenenitrile
3-(Benzo(1,3]dioxol-5-ylamino)-2-(2,2dimethyl-propionyl)-3-(1,1-dimethyl-propylamino) propenenitrile
2-(4-Chlorophenylsulfonyl)-3-(3-cyanophenylamino)-3-(1,2,2-trimethylpropylamino)-2propenenitrile
2-(4-Chlorophenylsulfonyl)-3-(3-cyanophenylamino)-3-cyclopentylamino-2-propenenitrile
2-(4-Chlorophenylsulfonyl)-3-(3-cyanophenylamino-3-(1,2-dimethylpropylamino)-2-propenenitrile
3-(3,5-Bis(trifluoromethyl)phenylamino)-2-isopropylsulfonyl-3-(1,2,2-trimethylpropylamino)-propenenitrile
3-(3,5-Bis(trifluoromethyl)phenylamino)-2-isopropylsulfonyl-3-cyclopentylamino-2-propenenitrile
3-(3,5-Bis(trifluoromethyl)phenylamino)-3-cyclobutylamino-2-isopropylsulfonyl-2-propenenitrile
3-(3,5-Bis(trifluoromethyl)phenylamino)-2-isopropylsulfonyl-3-(2-methyl)propylamino)-2-propenenitrile
2-Isopropylsulfonyl-3-(3-methoxyphenylamino)-3-(1,2,2-trimethylpropylamino)-2-propenenitrile
3-Cyclopentylamino-2-isopropylsulfonyl-3-(3-methoxy)phenylamino-2-propenenitrile
3-Cyclobutylamino-2-isopropylsulfonylamino-3-(3-methoxy)phenylamino-2-propenenitrile
2-Isopropylsulfonyl-3-(3-methoxy)phenylamino-3-(2-methyl)propylamino)-2-propenenitrile
3-(1,1-Dimethyl)propylamino)-2-isopropylsulfonyl-3-(3-methoxy)phenylamino-2-propenenitrile
2-Isopropylsulfonyl-3-(3-methoxy)phenylamino-3-tert.-butylamino-2-propenenitrile
3-(Benzo[1,3]dioxol-5-ylamino)-3-(1,1-dimethylpropylamino)-2-methanesulfonyl-2-propenenitrile
and pharmaceutically acceptable salts thereof.

### Claim 12

Compounds according to any one of the preceding claims which are active as potassium channel openers.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A pharmaceutical composition comprising a compound according to any of the claim 1-11 or a pharmaceutical acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form together with one or more pharmaceutically acceptable carriers or diluents.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A pharmaceutical composition for use in the treatment of diseases of the endocrinological system such as diabetes comprising a compound according to any of the claims 1-11 or a pharmaceutical acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form together with one or more pharmaceutically acceptable carriers or diluents.

### Claim 15 (depends on 13, 14)

The pharmaceutical composition according to claim 13 or 14 in the form of an oral dosage unit or parenteral dosage unit.

### Claim 16 (depends on 13, 14)

A pharmaceutical composition according to claim 13 or 14 wherein said compound is administered as a dose in a range from about 0.05 mg to 1000 mg, preferably from about 0.1 mg to 500 mg and especially in the range from 50 mg to 200 mg per day.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A compound according to any one of the claims 1-11 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form for therapeutical use.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A compound according to any one of the claims 1-11 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form for therapeutical use in the treatment or prevention of diseases of the endocrinological system, such as diabetes.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The use of a compound according to any one of the claims 1-11 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form as a medicament.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The use of a compound according to any of the claims 1-11 for preparing a medicament.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The use of a compound according to any one of the claims 1-11 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, including a racemic mixture, or any tautomeric form for the preparation of a medicament for the treatment or prevention of diseases of the endocrinological system, such as diabetes.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of treating or preventing diseases of the endocrinological system, such as diabetes in a subject in need thereof comprising administering an effective amount of a compound according to any of the claims 1-11 to said subject.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A process for the manufacture of a medicament to be used in the treatment or prevention of diseases of the endocrinological system, such as diabetes which process comprising bringing a compound of formula I according to any of the claims 1-11 or a pharmaceutically acceptable salt thereof into a galenic dosage form.

### Claim 24

A method of preparing a compound of formula I, comprising the following steps of reaction: 8
wherein acceptor substituted acetonitriles are reacted with isothiocyanates in the presence of a base and the resulting salts of the adducts are treated with alkyl halide to give the corresponding alkylsulfanyl propenenitriles, which are then reacted with primary and secondary amines to give cyanoenamines of formula I.

### Claim 25

Any novel feature or combination of features as described herein.
